PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research.

Abstract Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size. The main targets of ischemic stroke therapy aim to restore tissue perfusion in the ischemic penumbra in order to decrease the total infarct area by maintaining blood flow. Advances in research of pathological process and pathways during acute ischemia have resulted in improvement of new treatment strategies apart from restoring perfusion. Additionally, limiting the injury severity by manipulating the molecular mechanisms during ischemia has become a promising approach, especially in animal research. The purpose of this article is to review completed and ongoing phases I and II trials for the treatment of acute ischemic stroke, reviewing studies on antithrombotic, thrombolytic, neuroprotective, and antineuroinflammatory drugs that may translate into more effective treatments.
PMID
Related Publications

Acute antithrombotic treatment of ischemic stroke.

Pharmacotherapy of cerebral ischemia.

The role of diffusion- and perfusion-weighted magnetic resonance imaging in drug development for ischemic stroke: from laboratory to clinics.

The only evidence based neuroprotective therapy for acute ischemic stroke: thrombolysis.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Authors

Mayor MeshTerms
Keywords
Journal Title biomed research international
Publication Year Start




PMID- 28286764
OWN - NLM
STAT- MEDLINE
DA  - 20170313
DCOM- 20170317
LR  - 20170317
IS  - 2314-6141 (Electronic)
VI  - 2017
DP  - 2017
TI  - Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently 
      Studied Drugs in Clinical Research.
PG  - 4863079
LID - 10.1155/2017/4863079 [doi]
AB  - Acute ischemic stroke is a devastating cause of death and disability,
      consequences of which depend on the time from ischemia onset to treatment, the
      affected brain region, and its size. The main targets of ischemic stroke therapy 
      aim to restore tissue perfusion in the ischemic penumbra in order to decrease the
      total infarct area by maintaining blood flow. Advances in research of
      pathological process and pathways during acute ischemia have resulted in
      improvement of new treatment strategies apart from restoring perfusion.
      Additionally, limiting the injury severity by manipulating the molecular
      mechanisms during ischemia has become a promising approach, especially in animal 
      research. The purpose of this article is to review completed and ongoing phases I
      and II trials for the treatment of acute ischemic stroke, reviewing studies on
      antithrombotic, thrombolytic, neuroprotective, and antineuroinflammatory drugs
      that may translate into more effective treatments.
FAU - Reis, Cesar
AU  - Reis C
AD  - Department of Anesthesiology, Loma Linda University Medical Center, Loma Linda,
      CA 92354, USA.
FAU - Akyol, Onat
AU  - Akyol O
AD  - Department of Physiology and Pharmacology, Loma Linda University School of
      Medicine, 11041 Campus Street, Risley Hall, Room 219, Loma Linda, CA 92354, USA.
FAU - Ho, Wing Mann
AU  - Ho WM
AD  - Department of Neurosurgery, University Hospital Innsbruck, 6020 Tyrol, Austria;
      Department of Neurosurgery, Loma Linda University School of Medicine, Loma Linda,
      CA 92354, USA.
FAU - Araujo, Camila
AU  - Araujo C
AD  - Department of Physiology and Pharmacology, Loma Linda University School of
      Medicine, 11041 Campus Street, Risley Hall, Room 219, Loma Linda, CA 92354, USA.
FAU - Huang, Lei
AU  - Huang L
AD  - Department of Anesthesiology, Loma Linda University Medical Center, Loma Linda,
      CA 92354, USA.
FAU - Applegate Ii, Richard
AU  - Applegate Ii R
AD  - Department of Anesthesiology, Loma Linda University Medical Center, Loma Linda,
      CA 92354, USA.
FAU - Zhang, John H
AU  - Zhang JH
AUID- ORCID: 0000-0002-4319-4285
AD  - Department of Anesthesiology, Loma Linda University Medical Center, Loma Linda,
      CA 92354, USA; Department of Physiology and Pharmacology, Loma Linda University
      School of Medicine, 11041 Campus Street, Risley Hall, Room 219, Loma Linda, CA
      92354, USA; Department of Neurosurgery, Loma Linda University School of Medicine,
      Loma Linda, CA 92354, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170214
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Neuroprotective Agents)
SB  - IM
MH  - Acute Disease
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Brain Ischemia/*drug therapy
MH  - Clinical Trials, Phase I as Topic
MH  - Clinical Trials, Phase II as Topic
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Male
MH  - Neuroprotective Agents/*therapeutic use
MH  - Stroke/*drug therapy
PMC - PMC5329656
COI - The authors state no conflict of interests.
EDAT- 2017/03/14 06:00
MHDA- 2017/03/18 06:00
CRDT- 2017/03/14 06:00
PHST- 2016/09/27 [received]
PHST- 2016/11/23 [accepted]
AID - 10.1155/2017/4863079 [doi]
PST - ppublish
SO  - Biomed Res Int. 2017;2017:4863079. doi: 10.1155/2017/4863079. Epub 2017 Feb 14.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>